MC5-A Scrambler Therapy for the Treatment of Chronic Neuropathic Extremity Pain
NCT ID: NCT02701075
Last Updated: 2017-02-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
58 participants
INTERVENTIONAL
2013-09-30
2017-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Scrambler Therapy in the Treatment of Chronic Chemotherapy-Induced Peripheral Neuropathy
NCT02111174
MC5-A Scrambler Therapy in Reducing Peripheral Neuropathy Caused by Chemotherapy
NCT01290224
Scrambler Therapy for the Reduction of Chemotherapy-Induced Neuropathic Pain
NCT04239976
Electrical Stimulation Therapy Using the MC5-A Scrambler in Reducing Peripheral Neuropathy Caused by Chemotherapy
NCT00952848
Pediatric Electrocutaneous Analgesia for Children Experiencing Neuropathic Pain
NCT07264920
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
MC5-A Scrambler Therapy
MC5-A Scrambler Therapy is an electroanalgesia device that interferes with pain signal transmission by using nerve fibers as a passive means to convey a no pain message to the central nervous system. Electrodes are placed on dermatomes that correspond to the area of pain. Patient is treated for 30 minutes and given up to 10 treatment sessions.
MC5-A Scrambler Therapy
up to 10 sessions, each session lasting 30 minutes
MC5-A Scrambler Therapy Sham Device
The MC5-A Scrambler Therapy Device will be used as an active sham device in this randomized double blind study. Participants assigned to this arm will not receive active therapy.
MC5-A Scrambler Therapy Sham Device
up to 10 sessions, each session lasting 30 minutes
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
MC5-A Scrambler Therapy
up to 10 sessions, each session lasting 30 minutes
MC5-A Scrambler Therapy Sham Device
up to 10 sessions, each session lasting 30 minutes
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* neuropathic pain symptoms present for 3 months or greater prior to entry into the study
* rated pain intensity equal to or greater than 3 on NRS-11 pain scale
* painful peripheral neuropathy in an extremity that is the result of a traumatic injury (post-traumatic/ post-surgical neuropathy, stump pain, entrapment neuropathy), or low back pain with radiculopathy
* stable pain medication treatment regimen
* able to speak and read English, understand the study procedures, and consent to study participation
Exclusion Criteria
* vena cava, aneurysm clips, coronary or other vascular stents
* pregnancy via a pregnancy test
* history of epilepsy, brain injury, symptomatic brain metastases
* prior celiac plexus block, or other neurolytic pain control treatment, within 4 weeks
* wounds or skin irritation in areas where the electrodes are required to be placed
* cardiac ischemia within the previous 6 months
* severe arrhythmia
* documented history of moderate or severe traumatic brain injury
* latex allergies
* open wound over site of chronic pain
* unable to stop anti-epileptic medications or gabapentin over 2 weeks of MC5-A ST treatment
* history of electroanalgesia treatment (electroacupuncture, biomodulator, TENS) over last 30 days
* participation in the study would delay the medical board (MEB) processing of the service member off of active duty status or would delay a return to duty status to their home unit.
* metal implants such as cardiac pacemakers, automatic defibrillators, aneurysm clips, vena cava clips and skull plates
18 Years
79 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Brooke Army Medical Center
FED
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ann Marie Nayback-Beebe, PhD, RN
LTC Ann Marie Nayback-Beebe
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ann Marie Nayback-Beebe, PhD, FNP-BC
Role: PRINCIPAL_INVESTIGATOR
Brooke Army Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Brooke Army Medical Center
Fort Sam Houston, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TSNRP-N13-04
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.